SAFits, a selective inhibitor of KBP51, reduced PD-L1 expression and PD-L1-induced cell death in coculture of peripheral blood mononuclear cells with glioma cells. This indicates a potential immunomodulatory strategy for treating glioblastoma. This evidence concerns the gene CD274 and central nervous system cancer.